I-CBP112 has been used in cell culture and sample preparation, to verify the acetylation of VPS34 (vacuolar protein sorting 34), by p300 at K29, K771 and K781 and to diminish synergistic gene expression.

I-CBP112 is a selective inhibitor of the bromodomain-containing transcription factors CREBBP (CBP) and EP300 (IC₅₀ = 0.142 and 0.625 μM, respectively). I-CBP112 has little activity against other bromodomains at concentrations up to 1 mM. For full characterization details, please see I-CBP112 on the Structural Genomics Consortium (SGC) website.

To learn about other SGC chemical probes for epigenetic targets, visit sigma.com/sgc

I-CBP112 is a selective inhibitor of the bromodomain-containing transcription factors CREBBP (CBP) and EP300.

I-CBP112 is also known as (1-[7-(3,4-dimethoxyphenyl)-9-{[(3S)-1-methylpiperidin-3-yl]-methoxy}-2,3,4,5-tetrahydro-1,4-benzoxazepin-4-yl]propan-1-one). It has the ability to induce full-length p300/CBP nucleosome acetylation. It is a competitive inhibitor of acetyl-lysine. I-CBP112 regulates transcription of key inflammatory genes.

I-CBP112 is an epigenetic chemical probe available through a partnership with the Structural Genomics Consortium (SGC). To learn more and view other SGC epigenetic probes, visit sigma.com/SGC.

This compound is a featured product for Gene Regulation research. Click here to discover more featured Gene Regulation products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.

I-CBP112 has been expertly reviewed and recommended by the Chemical Probes Portal. For more information, please visit the I-CBP112 probe summary on the Chemical Probes Portal website.